[go: up one dir, main page]

GR3031919T3 - PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES. - Google Patents

PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES.

Info

Publication number
GR3031919T3
GR3031919T3 GR990403009T GR990403009T GR3031919T3 GR 3031919 T3 GR3031919 T3 GR 3031919T3 GR 990403009 T GR990403009 T GR 990403009T GR 990403009 T GR990403009 T GR 990403009T GR 3031919 T3 GR3031919 T3 GR 3031919T3
Authority
GR
Greece
Prior art keywords
human
protein
pct
lymphocytes
peptides
Prior art date
Application number
GR990403009T
Other languages
English (en)
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Original Assignee
Univ Leiden
Seed Capital Investments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Investments filed Critical Univ Leiden
Publication of GR3031919T3 publication Critical patent/GR3031919T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GR990403009T 1992-05-26 1999-11-19 PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES. GR3031919T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP92201510 1992-05-26
EP93913627A EP0643726B1 (en) 1992-05-26 1993-05-18 PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
PCT/NL1993/000102 WO1993024525A1 (en) 1992-05-26 1993-05-18 PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES

Publications (1)

Publication Number Publication Date
GR3031919T3 true GR3031919T3 (en) 2000-03-31

Family

ID=8210629

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990403009T GR3031919T3 (en) 1992-05-26 1999-11-19 PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES.

Country Status (11)

Country Link
US (1) US5679641A (el)
EP (1) EP0643726B1 (el)
JP (2) JPH08501280A (el)
AT (1) ATE183514T1 (el)
AU (1) AU681853B2 (el)
CA (1) CA2136624A1 (el)
DE (1) DE69326064T2 (el)
DK (1) DK0643726T3 (el)
ES (1) ES2139012T3 (el)
GR (1) GR3031919T3 (el)
WO (1) WO1993024525A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
AU7478394A (en) * 1993-08-06 1995-02-28 Cytel Corporation Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
JPH10510988A (ja) 1994-12-14 1998-10-27 ザ スクリップス リサーチ インスティテュート 腫瘍−特異的細胞毒性ｔ細胞のインビボ活性化
US5925799A (en) * 1996-03-12 1999-07-20 Abb Lummus Global Inc. Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP1950224A3 (en) * 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) * 1998-05-14 1998-05-14 Karolinska Innovations Ab Inhibition of p53 function by a p53-derived peptide
DE69940774D1 (de) * 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
TW410377B (en) * 1999-06-17 2000-11-01 Taiwan Semiconductor Mfg Method of planarization and the apparatus of the same
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP1237564A4 (en) * 1999-12-10 2005-05-04 Epimmune Inc TRIGGERING OF CELLULAR IMMUNE RESPONSES AGAINST P53 USING NUCLEIC ACID AND PEPTIDE COMPOSITIONS
US20030144474A1 (en) * 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
JP4447456B2 (ja) 2001-06-05 2010-04-07 アルトール バイオサイエンス コーポレーション Ｐ５３結合ｔ細胞受容体分子とその使用
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
JP2008544962A (ja) * 2005-05-12 2008-12-11 イントロゲン セラピューティックス， インコーポレイテッド 癌の治療のためのｐ５３ワクチン
CA2662798A1 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
US20110053849A1 (en) * 2006-08-17 2011-03-03 Salomon Amar Regulation of litaf modulated cytokine production by a novel p53 short peptide
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

Also Published As

Publication number Publication date
ATE183514T1 (de) 1999-09-15
DE69326064T2 (de) 2000-05-25
US5679641A (en) 1997-10-21
CA2136624A1 (en) 1993-12-09
AU681853B2 (en) 1997-09-11
EP0643726B1 (en) 1999-08-18
DK0643726T3 (da) 2000-03-20
EP0643726A1 (en) 1995-03-22
JP2004123708A (ja) 2004-04-22
AU4359193A (en) 1993-12-30
WO1993024525A1 (en) 1993-12-09
JPH08501280A (ja) 1996-02-13
ES2139012T3 (es) 2000-02-01
DE69326064D1 (de) 1999-09-23

Similar Documents

Publication Publication Date Title
GR3031919T3 (en) PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES.
IL105554A0 (en) Peptides of human papilloma virus for use in human t cell response inducing compositions
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
DE69726426D1 (de) Unterdrückung von immunantwort durch hemmung von cathepsin s
TR199501630A2 (tr) Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar.
ATE63126T1 (de) Tetra- und penta-peptide mit der sequenz lysylarginyl-aspartyl, und ihre verwendung als antithrombotika.
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
GR3035152T3 (en) Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
CA2184175A1 (en) Isolated, tyrosinase derived peptides and uses thereof
NO964561D0 (no) Tri-, tetra-, penta-, og polypeptider, og bruken av disse som antidepressiv agent
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE3462692D1 (en) Pharmacologically active peptides
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
DE69733026D1 (de) Cyclin e spezifische konstrukte und komplexe
IL127080A0 (en) The use of peptides derived from zona pelucida proteins for contraception and pharmaceutical compositions containing the same
CA2247998A1 (en) Fragments of cr1 and their use
UA9703A (uk) Антипротеіназний засіб
PT999849E (pt) Utilizacao de lbp no tratamento da septicemia